About
Pheno Therapeutics is a clinical stage biotech company developing GPR17 antagonists for neurodegenerative and demyelinating disorders.
We are focussed on therapeutically targeting oligodendrocytes, a cell type in the brain that has roles in action potential conduction, trophic and metabolic support as well as axonal protection.
Oligodendrocytes are compromised in multiple CNS disorders, leading to demyelination due to an excess of inhibitory factors, of which GPR17 is one. By blocking the GPR17 receptor, the expression of which has been shown to be upregulated in diseased brains, we can unlock the brain’s endogenous repair systems which are inhibited by overexpression of GPR17.
Approach
We are dedicated to addressing the unmet need of disability progression in neurological diseases
Diseases such as multiple sclerosis, Alzheimer’s disease, ALS, Parkinson’s disease and rare disorders including the leukodystrophies, neuromyelitis optica spectrum disorder, periventricular leukomalacia and myelin oligodendrocyte glycoprotein antibody-associated disease.
View Pipeline
Pipeline
We aim to dramatically transform the quality of life for patients and their families suffering from these debilitating diseases
Pheno Therapuetics are an experienced, entrepreneurial team of biotech executives and academic Key Opinion Leaders.
Team
Latest News
We aim to discover, develop and deliver first and best in class oligodendrocyte based neuroprotective therapeutics for multiple sclerosis and other neurological disorders of high unmet medical need.
If you would like to find more, please get in touch.
Contact